Pharmaceutical
Ananda Pharma Confirms Safety of MRX1 CBD Drug, as Clinical Pain Trials Approach
Ananda Pharma has taken another major step forward in bringing its flagship MRX1 CBD oral solution to market.
MHRA
11stories
17 Junlast updated
More in MHRA
- Medical Cannabis
Curaleaf Laboratories Enters Strategic Partnership with ANTG to Manufacture and Distribute Medicinal Cannabis Products in the UK
Curaleaf Laboratories, one of the UK’s leading providers of medicinal cannabis products, is pleased to announce a landmark partnership with Australian Natural Therapeutics Group (ANTG), one of Australia’s most respected producers of pharmaceutical-grade medicinal cannabis.
- Pharmaceutical
Europe’s First Ever ‘Whole Plant’ Cannabis Medicine Could be Available by 2026 in Major Step Forward for Non-Opioid Pain Treatment
German pharmaceutical company Vertanical believes it is on course to deliver the first ‘whole-plant’, cannabis medicine with international approval.
- CBD Market
UK’s FSA Softens Stance on 0% THC in CBD Products, as MHRA Draws Clear Line on CBD Medical Claims
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Food Standards Agency (FSA) have both issued regulatory updates on CBD this week.
- Opinion
What’s in Store for the European Cannabis Industry in 2025? (Part 2)
Written by Ben Stevens and Sarah Sinclair. You can read Part 1 here.
- Medical
Parents of Children with Epilepsy Demand Urgent NHS Reform for Cannabis Access
Families from across the UK returned to Westminster on Tuesday 5 November, clutching photos of their loved ones, along with stories and testimonies from dozens of patients who say they are thriving thanks to cannabis-based medicines.
- Opinion
MHRA Clarification Is A Step In The Right Direction, Says CIC
IN November 2022, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) released new detailed guidelines for medical cannabis companies operating in the UK, providing a step-by-step plan for those ‘that do not already hold the necessary authorisations’ to begin producing cannabis-based medicinal products and APIs.
- Medical
MHRA’s New Guidance Points To A ‘Truly Pharmaceutical Path’ For UK Medical Cannabis And Could See End To ‘GACP To GMP Washing’
THE UK’s Medicines and Healthcare products Regulatory Agency (MHRA) last week released new detailed guidelines for medical cannabis companies operating in the UK.
